COVID-19 outcomes in patients with Dermatomyositis: A registry-based cohort analysis

Pakhchanian, Haig; Khan, Hiba; Raiker, Rahul; Ahmed, Sakir; Kavadichanda, Chengappa G; Abbasi, Maryam; Kardeş, Sinan; Agarwal, Vikas; Aggarwal, Rohit; Gupta, Latika

doi:10.1016/j.semarthrit.2022.152034

Cited by 14 publications

(16 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, all-cause hospitalizations in IIMs patients were higher than in patients with other SAIDs (30 versus 17%, respectively). Considering that IS/IM therapies are a known risk factor for worst outcomes in COVID-19 [ 9 , 11 , 14 ], our sample of patients with IIMs was more on IS/IM therapy than patients with other SAIDs, which may explain this finding. It is unclear why IIMs patients with BI had a lower incidence of headache and shorter duration of COVID-19 symptoms than patients with other SAIDs; this may represent a unique feature of COVID-19 in this subset of patients, which needs to be confirmed in future studies, or more probably a spurious finding owing to few BI cases in the IIMs group.…”

Section: Discussionmentioning

confidence: 98%

“…Patients with SAIDs, including IIMs, are a vulnerable population at an increased risk of disease severity and poorer clinical outcomes related to COVID-19 infection and possibly a higher incidence of COVID-19 infection compared to healthy counterparts [ 10 , 13 , 14 ]. We found a reported frequency of COVID-19 of 6.2% in IIMs patients and 10.5% in SAIDs before vaccination, which is higher than the rate of 0.36% previously reported in a systematic review of patients with inflammatory and autoimmune rheumatic diseases [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, despite some contradictory data regarding the incidence of COVID-19 infection among patients with autoimmune rheumatic diseases versus the general population, a recent systematic review and meta-analysis of 100 studies has demonstrated that patients with rheumatic and musculoskeletal diseases have a higher rate of SARS-CoV-2 infection and increased odds of mortality [ 13 ]. COVID-19 characteristics and outcomes are usually studied in patients with SAIDs as a large group [ 1 , 5 – 10 , 13 ], but specific data about COVID-19 in the subset of IIMs patients are scarce [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey

Hoff

Naveen²,

Shinjo³

et al. 2022

Rheumatol Int

View full text Add to dashboard Cite

Objectives We aimed to compare the spectrum and severity of COVID-19 and vaccine breakthrough infections (BIs) among patients with IIMs, other systemic autoimmune and inflammatory diseases (SAIDs), and healthy controls (HCs). Methods This is a cross-sectional study with data from the COVAD study, a self-reported online global survey that collected demographics, COVID-19 history, and vaccination details from April to September 2021. Adult patients with at least one COVID-19 vaccine dose were included. BIs were defined as infections occurring > 2 weeks after any dose of vaccine. Characteristics associated with BI were analyzed with a multivariate regression analysis. Results Among 10,900 respondents [42 (30–55) years, 74%-females, 45%-Caucasians] HCs were (47%), SAIDs (42%) and IIMs (11%). Patients with IIMs reported fewer COVID-19 cases before vaccination (6.2%-IIM vs 10.5%-SAIDs vs 14.6%-HC; OR = 0.6, 95% CI 0.4–0.8, and OR = 0.3, 95% CI 0.2–0.5, respectively). BIs were uncommon (1.4%-IIM; 1.9%-SAIDs; 3.2%-HC) and occurred in 17 IIM patients, 13 of whom were on immunosuppressants, and 3(18%) required hospitalization. All-cause hospitalization was higher in patients with IIM compared to HCs [23 (30%) vs 59 (8%), OR = 2.5, 95% CI 1.2–5.1 before vaccination, and 3 (18%) vs 9 (5%), OR = 2.6, 95% CI 1.3–5.3 in BI]. In a multivariate regression analysis, age 30–60 years was associated with a lower odds of BI (OR = 0.7, 95% CI 0.5–1.0), while the use of immunosuppressants had a higher odds of BI (OR = 1.6, 95% CI 1.1–2.7). Conclusions Patients with IIMs reported fewer COVID-19 cases than HCs and other SAIDs, but had higher odds of all-cause hospitalization from COVID-19 than HCs. BIs were associated with the use of immunosuppressants and were uncommon in IIMs.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey

Hoff

Naveen²,

Shinjo³

et al. 2022

Rheumatol Int

View full text Add to dashboard Cite

show abstract

“…We want to sincerely thank Dr. Wen-Jiun et al for their interest in our article “COVID-19 outcomes in patients with Dermatomyositis: A registry-based cohort analysis 1 ” and will share several thoughts and responses.…”

mentioning

confidence: 99%

Reply to “Letter to the Editor Regarding ‘COVID-19 outcomes in patients with Dermatomyositis: A registry-based cohort analysis’”

Pakhchanian

Raiker

Agarwal

et al. 2023

Seminars in Arthritis and Rheumatism

Self Cite

View full text Add to dashboard Cite

“…We read with great interest the article by Haig Pakhchanian et al regarding the COVID-19 outcomes in patients with Dermatomyositis: A registry-based cohort analysis [1] . We appreciated the results of Dermatomyositis patients may not have a worsening outcome of COVID-19 infection, including severe symptoms of COVID-19 infection, mortality, and sepsis, etc.…”

mentioning

confidence: 99%

Letter to the Editor regarding “COVID-19 outcomes in patients with dermatomyositis: A registry-based cohort analysis”

Lin

Shih

Wei

2023

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

COVID-19 outcomes in patients with Dermatomyositis: A registry-based cohort analysis

Cited by 14 publications

References 45 publications

COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey

COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey

Reply to “Letter to the Editor Regarding ‘COVID-19 outcomes in patients with Dermatomyositis: A registry-based cohort analysis’”

Letter to the Editor regarding “COVID-19 outcomes in patients with dermatomyositis: A registry-based cohort analysis”

Contact Info

Product

Resources

About